中华预防医学杂志
中華預防醫學雜誌
중화예방의학잡지
CHINESE JOURNAL OF
2008年
10期
753-757
,共5页
周晓星%张波%黄莉莉%许颖%孙丽娜%卓淑雨%陈裕明%苏宜香
週曉星%張波%黃莉莉%許穎%孫麗娜%卓淑雨%陳裕明%囌宜香
주효성%장파%황리리%허영%손려나%탁숙우%진유명%소의향
脂肪酸类%高脂血症%膳食脂肪类
脂肪痠類%高脂血癥%膳食脂肪類
지방산류%고지혈증%선식지방류
Fatty acids%Hyperlipidemias%Dietary fats
目的 研究高胆固醇血症患者膳食脂肪摄入与血脂变化之间的关系.方法 筛查739名志愿者后,纳入297例血清总胆固醇(TC)5.13 mmol/L的广州市民,随访6个月,采用连续3 d的24 h膳食回顾法及食用油种类及用量记录表调查研究对象膳食摄入情况,并测定研究对象在研究起始和结束时的血脂水平,分析不同膳食脂肪供能比及脂肪酸供能比与血脂变化的关系.结果 纳入研究对象297例,其中281例(男88例,女193例)完成6个月的研究,研究起始时对象的TC为(6.09±0.68)mmot/L.将研究对象按照总脂供能比,分为<25%(90例),25%~30%(97例),30%(94例)3组,总脂供能比≤30%的Ⅰ组及Ⅱ组TC、低密度脂蛋白胆固醇(LDL-C)降低率大于总脂供能比30%的Ⅲ组.将研究对象按照饱和脂肪酸(SFA)供能比分为<7%(81例),7%~10%(129例),10%(71例)3组,SFA供能比≤10%的Ⅰ组和Ⅱ组TC、LDL-C降低率大于SFA供能比10%的Ⅲ组.将研究对象按照单不饱和脂肪酸(MUFA)供能比分为<10%(93例),10%~13%(106例),13%(82例)3组,MUFA供能比为10%~13%的Ⅱ组,代和LDL-C降低率大于另外两组.将研究对象按照多不饱和脂肪酸(PUFA)供能比分为<7%(88例),7%~9%(94例),9%(99例)3组,未发现3组间血脂降低率差异有统计学意义.结论 对于血脂异常患者,总脂供能比≤30%,SFA供能比≤10%,MUFA供能比在10%~13%的范围有利于改善其血脂水平.
目的 研究高膽固醇血癥患者膳食脂肪攝入與血脂變化之間的關繫.方法 篩查739名誌願者後,納入297例血清總膽固醇(TC)5.13 mmol/L的廣州市民,隨訪6箇月,採用連續3 d的24 h膳食迴顧法及食用油種類及用量記錄錶調查研究對象膳食攝入情況,併測定研究對象在研究起始和結束時的血脂水平,分析不同膳食脂肪供能比及脂肪痠供能比與血脂變化的關繫.結果 納入研究對象297例,其中281例(男88例,女193例)完成6箇月的研究,研究起始時對象的TC為(6.09±0.68)mmot/L.將研究對象按照總脂供能比,分為<25%(90例),25%~30%(97例),30%(94例)3組,總脂供能比≤30%的Ⅰ組及Ⅱ組TC、低密度脂蛋白膽固醇(LDL-C)降低率大于總脂供能比30%的Ⅲ組.將研究對象按照飽和脂肪痠(SFA)供能比分為<7%(81例),7%~10%(129例),10%(71例)3組,SFA供能比≤10%的Ⅰ組和Ⅱ組TC、LDL-C降低率大于SFA供能比10%的Ⅲ組.將研究對象按照單不飽和脂肪痠(MUFA)供能比分為<10%(93例),10%~13%(106例),13%(82例)3組,MUFA供能比為10%~13%的Ⅱ組,代和LDL-C降低率大于另外兩組.將研究對象按照多不飽和脂肪痠(PUFA)供能比分為<7%(88例),7%~9%(94例),9%(99例)3組,未髮現3組間血脂降低率差異有統計學意義.結論 對于血脂異常患者,總脂供能比≤30%,SFA供能比≤10%,MUFA供能比在10%~13%的範圍有利于改善其血脂水平.
목적 연구고담고순혈증환자선식지방섭입여혈지변화지간적관계.방법 사사739명지원자후,납입297례혈청총담고순(TC)5.13 mmol/L적엄주시민,수방6개월,채용련속3 d적24 h선식회고법급식용유충류급용량기록표조사연구대상선식섭입정황,병측정연구대상재연구기시화결속시적혈지수평,분석불동선식지방공능비급지방산공능비여혈지변화적관계.결과 납입연구대상297례,기중281례(남88례,녀193례)완성6개월적연구,연구기시시대상적TC위(6.09±0.68)mmot/L.장연구대상안조총지공능비,분위<25%(90례),25%~30%(97례),30%(94례)3조,총지공능비≤30%적Ⅰ조급Ⅱ조TC、저밀도지단백담고순(LDL-C)강저솔대우총지공능비30%적Ⅲ조.장연구대상안조포화지방산(SFA)공능비분위<7%(81례),7%~10%(129례),10%(71례)3조,SFA공능비≤10%적Ⅰ조화Ⅱ조TC、LDL-C강저솔대우SFA공능비10%적Ⅲ조.장연구대상안조단불포화지방산(MUFA)공능비분위<10%(93례),10%~13%(106례),13%(82례)3조,MUFA공능비위10%~13%적Ⅱ조,대화LDL-C강저솔대우령외량조.장연구대상안조다불포화지방산(PUFA)공능비분위<7%(88례),7%~9%(94례),9%(99례)3조,미발현3조간혈지강저솔차이유통계학의의.결론 대우혈지이상환자,총지공능비≤30%,SFA공능비≤10%,MUFA공능비재10%~13%적범위유리우개선기혈지수평.
Objective To study the effects of dietary fatty acids on the serum lipids in hyperoholestorolemic subjects. Methods All 297 residents with hypercholesterolemia were enrolled in Guangzhou. The dietary composition and the changes in serum lipid levels during the 6-month follow-up were analyzed. Results (1) 297 subjects were enrolled and 281 subjects (88 male, 193 female) completed the 6-month follow-up. The serum TC concentration of the subjects was (6. 09±0. 68) mmoL/L at baseline. (2) According to the percentage of energy from total fat, all of the subjects were divided into three groups, including total fat % en <25%( group Ⅰ, 90 subjects),25% -30% ( group Ⅱ, 97 subjects), 30% ( group Ⅲ, 94 subjects). The reduction of TC and LDL-C in group Ⅰ and group Ⅱ was greater than that in group Ⅲ. (3) According to the percentage of energy from SFA, all of the subjects were divided into three groups, including SFA % en < 7% ( groupⅠ, 81 subjects), 7% - 10% ( group Ⅱ, 129 subjects), 10% ( group Ⅲ, 71 subjects). The reduction Of TC and LDL-C in group Ⅰ and group Ⅱ was greater than that in group Ⅲ. (4) All of the subjects were divided into three groups, according to the percentage of energy from MUFA, including MUFA % en < 10% (group Ⅰ , 93 subjects), 10% - 13% ( group Ⅱ , 106 subjects), 13% ( group Ⅲ, 82 subjects). The reduction of TC and LDL-C in group Ⅱwas greater than that in group Ⅰ and group Ⅲ. ( 5 ) All of the subjects were divided into three groups according to the percentage of energy from PUFA, including PUFA % en <7% (88 subjects),7% -9% (94 subjects), 9% (99 subjects). No significant difference was found among the reduction of serum lipids in the three groups. Conclusion Dietary total fat % en ≤30%, SFAs % en ≤10% and MUFAs % en 10% - 13% should be conductive to reduce the serum lipids of patients with hyperlipidemia.